Brunsting-Perry Cicatricial Pemphigoid: Diagnosis & Care

Brunsting-Perry cicatricial pemphigoid is a rare autoimmune blistering skin disorder primarily affecting the head and neck region, characterized by tense blisters that heal with significant scarring. Unlike classic mucous membrane pemphigoid, which often involves mucous membranes with scarring, this variant shows limited mucosal involvement and focuses on cutaneous lesions. First described in 1957 by Brunsting and Perry, it represents a distinctive subtype within the pemphigoid spectrum, overlapping features with bullous pemphigoid, cicatricial pemphigoid, and epidermolysis bullosa acquisita.

What is Brunsting-Perry Cicatricial Pemphigoid?

Brunsting-Perry cicatricial pemphigoid (BPP) manifests as recurrent vesicles, bullae, erosions, and crusts predominantly on the scalp, face, and neck, evolving into atrophic scars and milia. The condition arises from an autoimmune attack on components of the dermal-epidermal junction, leading to subepidermal blister formation and subsequent fibrosis. It typically affects older adults, with a predilection for males over 60 years, though cases in females and younger patients occur. Lesions are often pruritic or tender, and sun exposure or trauma may trigger flares. With fewer than 100 cases reported worldwide, BPP remains a diagnostic challenge, frequently misdiagnosed as nonmelanoma skin cancer.

Who Gets Brunsting-Perry Cicatricial Pemphigoid?

BPP predominantly impacts individuals over 60 years, with a male-to-female ratio skewed toward males, though female cases are documented, particularly emphasizing its consideration in women with scalp cicatricial lesions. Risk factors include photodamaged skin, as lesions favor sun-exposed areas like the scalp vertex. Associations with internal malignancies, medications, or mechanical trauma have been proposed but not firmly established. Genetic predispositions are unclear, but the autoimmune nature suggests interplay of environmental triggers and immune dysregulation.

• Age: Primarily >60 years
• Gender: More common in males, but females affected
• Predisposing factors: Sun exposure, trauma

Clinical Features

The hallmark of BPP is the development of tense, pruritic bullae on the head and neck that rupture to form erosions, crusts, and heal with scarring, often leading to cicatricial alopecia on the scalp. Lesions may appear as solitary plaques or multiple, with erythematous bases, central erosion, peripheral atrophy, hypopigmentation, and prominent vasculature. Mucosal involvement is rare and non-scarring, distinguishing it from classic cicatricial pemphigoid. Progression can mimic squamous cell carcinoma, prompting unnecessary excisions.

Symptoms

• Tense blisters filled with clear fluid
• Itching or tenderness
• Weeping or crusted erosions
• Milia formation within scars
• Cicatricial alopecia

Complications

Scarring leads to permanent hair loss and cosmetic disfigurement, impacting psychosocial health. Secondary bacterial infections from erosions occur infrequently. Unlike mucous membrane pemphigoid, ocular or severe oral scarring is absent.

Diagnosis

Diagnosis relies on clinical presentation, histopathology, and immunofluorescence. Biopsy reveals subepidermal blisters with eosinophilic infiltrate, resembling bullous pemphigoid but with scarring absent in early lesions. Direct immunofluorescence (DIF) shows linear IgG and C3 along the basement membrane zone (BMZ), epidermal side on salt-split skin. Indirect immunofluorescence detects circulating antibodies in 20-30% of cases, targeting BP180, BP230, laminin 332, or collagen VII. Negative DIF does not exclude BPP.

Differential Diagnosis

• Bullous pemphigoid: Generalized blisters, less scarring, elderly
• Cicatricial pemphigoid: Mucosal scarring predominant
• Epidermolysis bullosa acquisita: Trauma-induced, collagen VII antibodies
• Nonmelanoma skin cancer: Scaly plaques mimicking SCC
• Discoid lupus erythematosus: Scarring alopecia without blisters

Treatment

Treatment aims to suppress autoimmunity, promote healing, and prevent scarring, mirroring cicatricial pemphigoid protocols. Mild cases respond to ultra-potent topical steroids like clobetasol propionate 0.05% ointment. Systemic corticosteroids (prednisone 0.5-1 mg/kg/day) are used for moderate disease, tapered with steroid-sparing agents.

• First-line: Clobetasol propionate topical
• Systemic: Prednisone, dapsone
• Immunosuppressants: Azathioprine, mycophenolate mofetil, methotrexate, cyclophosphamide
• Biologics: Rituximab (intralesional or IV), dupilumab
• Other: Intralesional steroids, antihistamines

Combination therapy yields 31% complete remission; topical monotherapy suffices for mild forms. Rituximab shows promise in refractory cases.

Prognosis and Prevention

BPP has a better prognosis than classic cicatricial pemphigoid or EBA, with many achieving remission, though scarring persists. Relapses occur upon tapering therapy. Sun protection prevents flares. Regular monitoring for new lesions is advised.

Frequently Asked Questions (FAQs)

What causes Brunsting-Perry cicatricial pemphigoid?

Autoantibodies target BMZ proteins like laminin 332, BP180/230.

Is Brunsting-Perry pemphigoid curable?

Not curative, but manageable with remission in many cases.

Can it affect mucous membranes?

Rarely, and without scarring, unlike classic forms.

How is it diagnosed?

By biopsy, DIF showing linear IgG/C3 at BMZ.

What is the best treatment?

Topical steroids for mild; systemic for severe.

Similar Articles

Alarming Rise in Self-Harm in Young People

Alarming Rise in Self-Harm in Young People

Skin Signs Of Non-Accidental Injury: Expert Guide For Clinicians

Lichen Simplex Of The Scrotum: Diagnosis And Treatment

Labial Adhesion In Prepubertal Girls: What Parents Need To Know

Thrush In Men: 5 Signs, Causes, And Treatment Options

Author

Sneha TeteBeauty & Lifestyle Writer

 

Sneha is a relationships and lifestyle writer with a strong foundation in applied linguistics and certified training in relationship coaching. She brings over five years of writing experience to renewcure,  crafting thoughtful, research-driven content that empowers readers to build healthier relationships, boost emotional well-being, and embrace holistic living.

Read full bio of Sneha Tete